TenNor Therapeutics
Latest round
- Series E
Last raised
- Oct 2024
Total raised
- $109M
Investors
- 18
About TenNor Therapeutics
Based in Suzhou, China, and founded in 2013, TenNor Therapeutics operates as a new antibacterial drug developer, engaged in the treatment of digestive tract infections of new drugs research and development, production and sales. Some enterprises, such as Peking University First Hospital, Beijing Yipukono Technology, and Wuxi New Drug Development, have cooperated with the company. The scientific advisor of the company, Xiaodong Wang, is a director of the Beijing Institute of Life Sciences. TenNor Therapeutics focuses on bacterial infection and bacterial metabolism-related diseases. The company has a multi-target coupled molecule new drug research and development platform. Its products include TNP-2092IV, TNP-2198, MDR-TB and other series. The products can be used to treat gastrointestinal infections associated with Helicobacter pylori and other pathogenic bacteria, artificial joint infections, bacterial vaginosis, drug-resistant tuberculosis and hospital-acquired gram-negative bacterial infections. The company generates revenue by developing drugs for the treatment of gastrointestinal infections.
Who invested in TenNor Therapeutics
18 investors across 6 rounds
See all investors in TenNor Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Questions about TenNor Therapeutics
Who invested in TenNor Therapeutics?
TenNor Therapeutics has 18 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TenNor Therapeutics raised?
TenNor Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did TenNor Therapeutics last raise money?
TenNor Therapeutics's most recent round on record is a Series E, in Oct 2024.
What does TenNor Therapeutics do?
Based in Suzhou, China, and founded in 2013, TenNor Therapeutics operates as a new antibacterial drug developer, engaged in the treatment of digestive tract infections of new drugs research and development, production and sales.
Where is TenNor Therapeutics headquartered?
TenNor Therapeutics is headquartered in Suzhou, China.
Which VCs invest in companies like TenNor Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at TenNor Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series E
Raising like TenNor Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.